Valuence Merger Corp I (VMCAF) is a special purpose acquisition company (SPAC) that seeks to identify and acquire a single operating business in Asia, excluding China, Hong Kong, and Macau, with a focus on life sciences or sustainable technology. The company holds IPO proceeds in a Trust Account and generates no operating revenue until a Business Combination is completed. As of December 31, 2025, the Trust Account held an estimated $12.43 per share available to public shareholders in the event of liquidation. The SPAC targets companies that can benefit from access to U.S. public capital markets and the management team's networks spanning both Asia and North America. Target sectors include biopharmaceuticals, clean technology, advanced transportation, industrial IoT, renewable energy, and sustainable agriculture. VMCA Sponsor, LLC held 74.7% of Class A ordinary shares and 100% of Class B ordinary shares as of the filing date. The company is led by President Sungsik (Sung) Lee and CFO Sungwoo (Andrew) Hyung, both with investment banking and M&A backgrounds in sustainability and technology.

Revenue model

No operating revenue. The company earns interest on Trust Account assets while searching for a Business Combination target. Economics for sponsors come at deal completion through founder share conversion, not from ongoing operations.

Products and services

Single-target Business Combination vehicle. Target sectors per the 10-K (filed 2026-03-31): life sciences (biopharmaceuticals, oncology, precision medicine, synthetic biology) and sustainable technology (clean technology, advanced transportation, industrial IoT, energy efficiency, renewable energy, sustainable agriculture, environmental services).

Customers and end markets

No commercial customers as a pre-combination SPAC. End markets sought in a target: biopharmaceutical therapeutics (oncology, cardiology, immunology, chronic disease), precision medicine, clean technology, and decarbonization-related industries across Asia excluding China, Hong Kong, and Macau.

Value-chain role

SPAC sponsor and acquisition vehicle. Sources, evaluates, and consummates a single Business Combination to bring an Asian operating company to U.S. public markets. Collaborates with CrystalBioSciences Co., Ltd (South Korean venture capital) and Credian Partners Inc. (private equity) for deal sourcing and diligence.

Geographic exposure

Target geography: Asia, explicitly excluding China, Hong Kong, and Macau. Management team has stated cross-border expertise spanning Asia and North America.

Source: SEC 10-K, filed 2026-03-31

Industry: Blank Checks